% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Zitricky:278420,
      author       = {F. Zitricky and A. Försti$^*$ and A. Hemminki and K.
                      Hemminki$^*$},
      title        = {{C}onditional survival in breast cancer up to 10 years in
                      the {N}ordic countries.},
      journal      = {Cancer medicine},
      volume       = {12},
      number       = {17},
      issn         = {2045-7634},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DKFZ-2023-01654},
      pages        = {17945-17951},
      year         = {2023},
      note         = {#LA:C020# / 2023 Sep;12(17):17945-17951},
      abstract     = {Survival in breast cancer (BC) has developed favorably but
                      late recurrences are still a problem.We model survival data
                      from the NORDCAN database and analyze 1-, 5-, and 10-year
                      relative survival and 5/1- and 10/5-year conditional
                      survival in BC from Denmark (DK), Finland (FI), Norway (NO),
                      and Sweden (SE) between 1971 and 2020. Conditional survival
                      measures survival in those who had survived year 1 to reach
                      year 5 (5/1), or in those who had survived year 5 to reach
                      year 10 (10/5).Almost all survival metrics were best for SE
                      but survival in all countries improved in the course of time
                      approaching the SE levels which were $98.3\%$ for 1-year,
                      $92.3\%$ for 5-year, and $87.8\%$ for 10-year survival.
                      Conditional 10/5-year survival, covering 5 years, was better
                      than 5/1-year survival, covering 4 years. A contributing
                      factor is most likely the high rate of recurrence in period
                      2-5 years. The difference was observed for all countries but
                      for DK 10/5-year survival approached 1-year survival and for
                      NO and SE 10/5-year survival was only barely better than
                      5/1-year survival. The explanation to this was the excellent
                      10/5-year survival in DK compared to SE and particularly to
                      NO. Literature search suggested that the reason for the
                      relatively low 10/5-year survival in NO might be stagnant
                      survival development in old patients.We assume that late
                      mortality is critically limiting survival in BC and either
                      interference with the late metastatic process or effective
                      treatment will be key to future improvements in BC
                      survival.},
      keywords     = {conditional survival (Other) / metastasis (Other) /
                      periodic survival (Other) / recurrence (Other) / screening
                      (Other) / treatment (Other)},
      cin          = {B062 / HD01 / C020},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331 /
                      I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37578395},
      doi          = {10.1002/cam4.6436},
      url          = {https://inrepo02.dkfz.de/record/278420},
}